Codexis, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alison Moore
- Full Time Employees
- 146
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 200 Penobscot Drive Redwood City CA United States of America 94063
- IPO Date
- Apr 22, 2010
- CIK
- 0001200375
- Website
- codexis.com
- Similar Companies
- Business
- Codexis, Inc. (NASDAQ:CDXS) develops and provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop and enhance novel high-performance enzymes; offers the ECO Synthesis manufacturing platform to enable scaled enzymatic manufacture of RNAi therapeutics including siRNA; provides pharma biocatalysis enzymes that optimize active pharmaceutical ingredient synthesis with greener processes, higher yields and reduced waste; delivers precision enzymes for molecular biology and diagnostic applications with improved fidelity, selectivity and activity; and supplies custom enzyme engineering services across pharmaceuticals, biotherapeutics and industrial biotechnology. The company operates in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia and China, targeting pharmaceutical companies, biopharma developers and diagnostic firms. Founded in 2002 and headquartered in Redwood City, California, Codexis focuses on sustainable manufacturing solutions for small molecule pharmaceuticals and nucleic acid synthesis. In recent developments, Codexis signed a $37.8 million Supply Assurance Agreement with Merck, announced organizational changes to streamline operations and reduce expenses, leased a GMP manufacturing facility to support scaled production, and entered an evaluation agreement with Nitto Denko Avecia to explore ECO Synthesis for therapeutic siRNA manufacturing; it also finalized an asset purchase agreement with Crosswalk Therapeutics in 2024 for investigational Fabry and Pompe disease gene therapy assets, monetizing non-core programs following a strategic shift.
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis Q2 Earnings Call Highlights
Codexis Reports Second Quarter 2026 Financial Results
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis to Report Second Quarter 2026 Financial Results on August 11
Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)
Codexis Announces Pricing of Public Offering of Common Stock
Codexis Announces Proposed Public Offering of Common Stock
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis Reports First Quarter 2026 Financial Results
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis to share RNA manufacturing advances at TIDES USA
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results